LifeVantage (LFVN) AI Stock Analysis

• Market Cap: $70.49M
• Dividend Yield: 2.81%
• Average Volume (3M): 200.39K
• Price to Earnings (P/E): 7.0
• Beta (1Y): <0.01
• Revenue Growth: 16.77%
• EPS Growth: 143.30%
• Country: US
• Employees: 222
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.02
• Shares Outstanding: 12,701,187
• 10 Day Avg. Volume: 304,350
• 30 Day Avg. Volume: 200,393
• PEG Ratio: 0.07
• Price to Book (P/B): 4.63
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 15.25
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 0.31
• Enterprise Value/Gross Profit: 0.39
• Enterprise Value/Ebitda: 5.19
• 1Y Price Target: $5.00
• Price Target Upside: -26.04% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $5.50 ▼(-18.64% Downside)

The score is held back primarily by weakening cash flow and recent revenue declines, reinforced by bearish technical signals (below key moving averages and negative MACD). Offsetting factors are an attractive valuation (low P/E and dividend yield) and guidance/capital-return actions, though near-term headwinds and leadership transition risk limit upside confidence.

Positive Factors

High Gross Margins & Improving Profitability

Sustained gross margins above ~80% underpin a durable competitive advantage in product economics, enabling the company to absorb sales volatility and fund R&D, marketing, and shareholder returns. Improved net margins indicate operating discipline that can support long-term profitability even if top-line growth is uneven.

Solid Balance Sheet & Manageable Leverage

A conservative leverage profile and positive equity position provide financial flexibility to pursue acquisitions, fund product launches, and return capital. With limited debt reliance the company can execute strategic initiatives and weather cyclical sales shocks without triggering solvency stress.

Acquisition Momentum & Product/Tech Innovation

The LoveBiome acquisition and patent-pending P84 broaden the product portfolio and diversify revenue away from a single recent launch; combined with a Shopify e-commerce modernization, these initiatives are structural levers to rebuild growth and improve direct-sell conversion over months.

Negative Factors

Revenue Volatility from GLP-1 Exposure

Heavy exposure to a GLP-1 system created material top-line volatility as pricing, insurance, and format shifts reduced demand; the one-time inventory reserve highlights obsolescence risk. Such product-specific swings can impair predictability of revenue and complicate distributor incentives over multiple quarters.

Weakened Cash Generation

A sharp decline in operating and free cash flow signals that earnings are converting to cash far less efficiently, limiting internal funding for marketing, inventory, and M&A. This reduces optionality for sustained buybacks or higher dividends if cash performance doesn't stabilize, and raises vulnerability to working-capital shocks.

Declining Active Accounts & MLM Engagement

A material drop in active distributor accounts undermines the core multi-level marketing sales engine, reducing recurring sales and network effects. Restoring distributor engagement typically requires sustained investment in incentives and product/tech improvements and can take several quarters to reverse, pressuring growth and margins.

LifeVantage Business Overview & Revenue Model

Company Description

LifeVantage Corporation engages in the identification, research, development, formulation, sale, and distribution of nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care products, bath and body, and targeted relief products. The company offers Protandim, a line of scientifically validated dietary supplements; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support digestive system health; a line of weight management products under the PhysIQ brand; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a line of energy drink mixes. It also provides anti-aging skin care products, including facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, the company offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website, as well as through a network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and China. LifeVantage Corporation is headquartered in Lehi, Utah.

How the Company Makes Money

LifeVantage generates revenue primarily through direct sales of its products, utilizing a multi-level marketing (MLM) business model. Independent distributors sell LifeVantage products directly to consumers and earn commissions based on their sales and the sales made by their recruited team members. This creates a tiered compensation structure that incentivizes recruitment and sales. Key revenue streams include product sales, distributor fees, and commissions from the MLM structure. Additionally, the company may engage in partnerships with other health and wellness brands or distributors to expand its market reach and enhance its product offerings, further contributing to its earnings.

LifeVantage Financial Statement Overview

Summary

Profitability improved meaningfully (very high gross margins and higher TTM net/operating margins) and leverage is manageable with strong ROE, but TTM revenue contraction and sharply weaker cash conversion/free cash flow are major offsets.

Income Statement

TTM (Trailing-Twelve-Months) revenue declined (-7.9%), following a stronger FY2025 (+14.2%) after a softer FY2024 (-6.2%), highlighting an uneven top-line trajectory. Profitability is a clear strength: gross margin remains exceptionally high (~80%+), and net margin improved materially versus FY2023–FY2024 (TTM ~4.8% vs ~1–1.5% previously), with EBIT/EBITDA margins also recovering into the mid-single digits. Overall, the income statement reflects a healthier profit profile, but recent revenue contraction keeps the score from the top tier.

Balance Sheet

Leverage looks manageable with debt-to-equity around ~0.34 in FY2025 and TTM, an improvement versus FY2024 (~0.52). Equity remains positive and the business is generating strong returns on equity (TTM ~38% and FY2025 ~28%), reflecting improved earnings power relative to the capital base. The main watch item is that total assets fell from FY2025 to TTM, but overall the balance sheet appears solid and not overly debt-dependent.

Cash Flow

Cash generation weakened meaningfully in TTM (Trailing-Twelve-Months): operating cash flow dropped to ~$3.7M and free cash flow to ~$1.7M, with free cash flow down sharply (-80.5%). While free cash flow remains close to net income (TTM ~0.86x), operating cash flow covers only about half of net income in TTM (~0.54x), indicating earnings are currently converting to cash less efficiently than in prior years (e.g., FY2025 operating cash flow was much stronger). This volatility and recent deterioration weigh on the score.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	228.53M	200.16M	213.40M	206.36M	220.18M
Gross Profit	183.67M	158.72M	170.01M	168.26M	181.99M
EBITDA	15.36M	7.91M	7.84M	7.96M	21.07M
Net Income	9.80M	2.94M	2.54M	3.12M	12.89M
Balance Sheet
Total Assets	71.96M	60.30M	66.12M	70.71M	78.73M
Cash, Cash Equivalents and Short-Term Investments	20.20M	16.89M	21.61M	20.19M	23.17M
Total Debt	11.68M	13.61M	13.09M	15.76M	18.18M
Total Liabilities	37.32M	34.31M	31.47M	39.19M	41.92M
Stockholders Equity	34.64M	25.99M	34.65M	31.52M	36.81M
Cash Flow
Free Cash Flow	10.51M	10.51M	3.76M	3.76M	12.53M
Operating Cash Flow	11.88M	11.88M	6.83M	6.83M	16.27M
Investing Cash Flow	-1.37M	-1.37M	-3.06M	-3.06M	-3.73M
Financing Cash Flow	-7.60M	-7.60M	-2.36M	-2.36M	-11.45M

LifeVantage Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFVN, the sentiment is Negative. The current price of 6.76 is above the 20-day moving average (MA) of 5.97, above the 50-day MA of 6.24, and below the 200-day MA of 10.05, indicating a bearish trend. The MACD of -0.25 indicates Positive momentum. The RSI at 41.76 is Neutral, neither overbought nor oversold. The STOCH value of 31.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFVN.

LifeVantage Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$453.14M	31.92	9.52%	―	6.62%	-7.85%
HLF	71 Outperform	$1.75B	5.41	―	―	-0.78%	265.56%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
LFVN	57 Neutral	$70.49M	6.96	33.31%	2.81%	16.77%	143.30%
USNA	56 Neutral	$382.07M	23.48	3.20%	―	5.88%	-68.62%
HAIN	45 Neutral	$106.87M	-0.20	-75.51%	―	-10.13%	-532.32%

LifeVantage Corporate Events

LifeVantage Reports Weaker Q2 Results, Launches Buyback Program

On January 30, 2026, LifeVantage announced that President and CEO Steven R. Fife plans to retire from his roles, including his board seat, with his resignation expected to take effect in April 2026, and the company emphasized that his decision was not related to any dispute over operations or financial policies. On February 4, 2026, the company reported that second-quarter fiscal 2026 revenue for the period ended December 31, 2025 fell 27.8% year on year to $48.9 million, with sharp declines in Americas sales and softer performance in Asia/Pacific and Europe, as the business cycled last year’s launch of the MindBody GLP-1 System™ and recorded lower profitability, including net income of $0.3 million, or $0.02 per diluted share, and adjusted EBITDA of $3.9 million. Management acknowledged competitive pressure in the weight-loss market and weaker-than-expected results, but pointed to growing momentum in the recently acquired LoveBiome® line, planned international expansion and new product launches as levers to restore growth, even as cash generation and cash balances declined over the first half of fiscal 2026 and gross margins were hit by inventory obsolescence tied to the GLP-1 product. Despite the earnings pressure, LifeVantage signaled confidence in its long-term strategy by unveiling a new $60 million share repurchase program to run through 2027, declaring a quarterly dividend of $0.045 per share payable March 16, 2026, and reiterating full-year fiscal 2026 guidance that foresees $185 million to $200 million in revenue and improved adjusted profitability, framing the current year as a transition period focused on portfolio diversification and shareholder returns.

The most recent analyst rating on (LFVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.

LifeVantage Announces Resignation of Two Key Executives

On December 3, 2025, LifeVantage Corporation announced the resignations of two key executives. Julie Boyster, the Chief Marketing Officer, will leave her position on December 12, 2025, and Todd Thompson, the Chief Information and Innovation Officer, will depart on December 24, 2025, both to pursue other business opportunities.

The most recent analyst rating on (LFVN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.

LifeVantage Holds Annual Stockholders Meeting, Elects Directors

LifeVantage Corporation held its fiscal year 2026 annual meeting of stockholders on November 6, 2025, where 75.41% of the company’s common stock was represented. During the meeting, stockholders elected seven directors to the board, approved executive compensation on an advisory basis, ratified Deloitte & Touche as the independent accounting firm, and approved an amendment to the 2017 Long-Term Incentive Plan.

The most recent analyst rating on (LFVN) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on LifeVantage stock, see the LFVN Stock Forecast page.